Phaseline

Companies › Baxalta now part of Shire

Baxalta now part of Shire: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Jan 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AskBio009 (BAX 335)
Adeno-associated virus serotype 8 (AAV8) delivering Factor IX (FIX) gene therapy
F9Phase 1Hemophilia BJan 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01687608AskBio009 (BAX 335)Phase 1Hemophilia BHematologyJan 2030

Targets

F9 (1)

Companies with the same targets

CSL Behring BioMarin Pharmaceutical Pfizer Roche Shanghai Xinzhi BioMed IntraBio Biocad Regeneron Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.